Fate Therapeutics (NASDAQ:FATE - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $1.16 million for the quarter.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,318.93% and a negative return on equity of 47.17%. The company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.18 million. On average, analysts expect Fate Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fate Therapeutics Price Performance
FATE stock traded down $0.04 during trading on Thursday, hitting $1.01. 195,462 shares of the stock traded hands, compared to its average volume of 2,049,371. Fate Therapeutics has a 1 year low of $0.66 and a 1 year high of $4.20. The firm's 50 day moving average is $1.21 and its two-hundred day moving average is $1.16. The stock has a market cap of $115.17 million, a price-to-earnings ratio of -0.67 and a beta of 2.24.
Hedge Funds Weigh In On Fate Therapeutics
Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in shares of Fate Therapeutics by 296.4% in the 1st quarter. AQR Capital Management LLC now owns 585,025 shares of the biopharmaceutical company's stock worth $462,000 after purchasing an additional 437,423 shares during the period. Comerica Bank lifted its stake in shares of Fate Therapeutics by 55,698.6% in the 1st quarter. Comerica Bank now owns 82,024 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 81,877 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 32,911 shares during the period. Institutional investors own 97.54% of the company's stock.
Analyst Upgrades and Downgrades
FATE has been the topic of several recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, June 12th. Robert W. Baird cut their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Barclays cut their price objective on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Fate Therapeutics currently has an average rating of "Hold" and a consensus price target of $3.83.
Check Out Our Latest Research Report on Fate Therapeutics
About Fate Therapeutics
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
